Contrast-Induced Nephropathy Post Percutaneous Interventional Procedures



CIN is associated with increased morbidity and mortality, prolonged hospitalization, and increased healthcare costs. It is the third leading cause of hospital-acquired renal failure. The incidence of contrast-induced nephropathy (CIN) after cardiac catheterization reported in literature is 3–22 % [1–3]. CIN has been shown to be associated with additional morbidity, mortality, and increased healthcare costs [1, 2]. Although the mechanism for CIN is not understood, several mechanisms have been implicated in the pathogenesis of this complex phenomenon including direct cytotoxic effects of the contrast agents, ischemic injury due to renal vasoconstriction, decreases in renal medullary blood flow, auto- and paracrine effects (including adenosine, endothelin, and reactive oxygen species activity), oxidative stress, and cellular apoptosis [3]. Risk stratification prior to catheterization perhaps can help identify patients at high risk for CIN.


Acute Kidney Injury Cardiac Catheterization Atrial Natriuretic Peptide Acute Decompensated Heart Failure Aminoglycoside Antibiotic 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105(19):2259–64.PubMedCrossRefGoogle Scholar
  2. 2.
    McCullough PA, Wolyn R, Rocher LL, Levin RN, O’Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997;103(5):368–75.PubMedCrossRefGoogle Scholar
  3. 3.
    Deek H, Newton P, Sheerin N, Noureddine S, Davidson PM. Contrast media induced nephropathy: a literature review of the available evidence and recommendations for practice. Aust Crit Care. 2014;pii:S1036-7314(13)00266-X. doi: 10.1016/j.aucc.2013.12.002. [Epub ahead of print] PubMed PMID: 24461960.
  4. 4.
    Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1–138.Google Scholar
  5. 5.
    Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44(7):1393–9.PubMedGoogle Scholar
  6. 6.
    Bartholomew BA, Harjai KJ, Dukkipati S, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol. 2004;93(12):1515–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Marenzi G, Lauri G, Campodonico J, Marana I, Assanelli E, De Metrio M, Grazi M, Veglia F, Fabbiocchi F, Montorsi P, Bartorelli AL. Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients. Am J Med. 2006;119(2):155–62. PubMed PMID: 16443418.PubMedCrossRefGoogle Scholar
  8. 8.
    Marenzi G, Bartorelli AL. Hemofiltration in the prevention of radiocontrast agent induced nephropathy. Minerva Anestesiol. 2004;70(4):189–91. PubMed PMID: 15173694.PubMedGoogle Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  1. 1.Department of Interventional CardiologyMount Sinai HospitalNew YorkUSA

Personalised recommendations